Palisade Bio director buys 50,000 shares for $50,500
Director Robert Baltera expanded his direct stake by nearly 11% shortly after the biopharmaceutical developer missed quarterly earnings forecasts.

Palisade Bio director Robert Baltera purchased 50,000 shares of the biopharmaceutical company for $50,500 on Nov. 17, according to a Securities and Exchange Commission filing.
The transaction increased Baltera's direct holding by 10.82% to 511,904 shares, coming one week after the company posted a wider-than-expected quarterly loss of $0.07 per share.
Baltera acquired the shares at an average price of $1.01 each. Based on the acquisition price, the director's total equity position reached approximately $517,023.
Palisade Bio stock fell $0.02 to $0.93 during mid-day trading on Thursday, hovering near its 52-week low of $0.92 and below its 50-day moving average of $1.41. The company has a market capitalisation of $165.90 million.
The insider purchase followed third-quarter financial results published Nov. 10, when the gastrointestinal therapy developer missed analyst consensus estimates by $0.01. Research analysts expect the firm to post a loss of $0.24 per share for the full fiscal year.
Palisade Bio is developing oral therapies for inflammatory bowel conditions, including PALI-2108 for ulcerative colitis and Crohn's disease, and LB1148 for postoperative bowel recovery. Institutional investors hold 11.79% of the company's shares.
Source: Securities and Exchange Commission Form 4 filing, Nov. 19, 2026.
More stories
- Greece targets 2.3% growth in 2027 budget
- US stocks face Goldman warning on further forced selling
- Bitcoin falls below $57,742 as investors seek other bets
- Nvidia SEC probe examines chipmaker’s accounting issues
- Rwanda women-owned exports fall 51% from 2021 peak
- Nasdaq rout tests IPO appetite as Anthropic gains retreat
- Investors value Anthropic at $2 trillion on Nasdaq debut
- Ubisoft H1 bookings fall 16.5% as it cuts 166 Canada jobs
- Zurich couples keep €9,140 after rent in Deutsche Bank gauge
- Anthropic IPO plans take focus as smaller US deals stall
Latest news
- Social Security raises 2027 benefits 3.6%
- Hull City 2–0 Brighton: When Resilience Beat Reputation
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence

